blood cancer – media

Luspatercept Passes Phase 3 Clinical Trial for Rare Blood Disease

Acceleron Pharma and its partner Celgene have revealed that luspatercept hit its primary and secondary endpoints in phase 3 clinical trial of patients affected with chronic anemia associated with a rare blood disease.
- Source: FierceBiotech
- 661
- July 3, 2018
blood cancer Clinical Trial
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.
- Source: tcr2
- 498
- March 23, 2018
blood cancer Market Views solid tumor TCR
Tmunity nabs $100M for next-gen T-cell immunotherapies

Tmunity Therapeutics is looking to bring better and safer T-cell therapies for both solid tumors and blood cancers and has scored a $100 million series A to propel it on its journey
- Source: fiercebiotech
- 505
- January 26, 2018
blood cancer Series solid tumor T-cell therapies
Blood cancer care needs improving, finds MP inquiry

The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
- Source: pharmatimes
- 649
- January 19, 2018
blood cancer NHS polices
Unforeseen new drug target discovered for acute myeloid leukemia

A study has found an unexpected new drug target for acute myeloid leukaemia (AML) that could open new avenues to develop effective treatments against this potentially lethal disease. Researchers from the Wellcome Trust Sanger Institute, the Gurdon Institute and their collaborators show that inhibiting the METTL3 gene destroys human and mouse AML cells without harming non-leukaemic blood cells.
- Source: medicalxpress
- 574
- November 28, 2017
AML blood cancer Chemotherapy leukaemia Researches
AstraZeneca admits cancer data for acquired drug was fabricated

AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.
- Source: Pharmafile
- 637
- October 19, 2017
acalabrutinib AstraZeneca blood cancer solid tumour

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.